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Successful treatment with voriconazole of cerebral
aspergillosis in an hematologic patient
Invasive aspergillosis in hematologic patients is
an opportunistic infection difficult to treat. The
infection localisation in the central nervous system
has a high mortality rate. We describe a patient
with advanced chronic lymphocytic leukaemia
with a high grade of immunodepression, who
developed pulmonary and cerebral aspergillosis
resistant to amphotericin B deoxycolate during
treatment with humanised monoclonal antibody
anti CD52. After 20 days of amphotericin B thera-
py (total dose 775 mg) a magnetic resonance imag-
ing of the brain and CT scan of the chest showed
cerebral lesion and increased size of the pul-
monary localisation. Oral therapy with voricona-
zole (until death after 7 months) permitted the
continuation of palliative chemotherapy and
resulted in complete resolution of the cerebral
lesions and marked an improvement of the pul-
monary lesionHaematologica 2007; 88:(2)e16-e18
Aspergillosis is a fungal infection not rare in hemato-
logic patients. The main localisation is usually in the lung
; the embolic dissemination in the central nervous sys-
tem carries a high mortality rate in the immunocompro-
mised 1-6.
Voriconazole is a new triazole with in vitro and in
vivo activity against a wide range of fungal pathogens
including Aspergillus species.
This report describes a case of pulmonary aspergillo-
sis with concomitant cerebral localisation in a patient
with advanced chronic lymphocytic leukaemia treated
successfully with oral voriconazole.
A 53 year old woman affected by chronic lymphocyt-
ic leukaemia since September 1995, developed a disease
progression with increasing lymphocytosis, multiple
lymph nodes and diffuse marrow involvement in May
1996. She was treated with chlorambucil at a dose of 40
mg/mq every month for six months, obtaining improve-
ment. In November 1998, because of disease progres-
sion, she was treated again with chlorambucil for three
months without remission. Then she underwent multi-
ple chemotherapy cycles without improvement: 1 cycle
with fludarabine (30mg/mq) and cyclophosphamide
(300 mg/mq) intravenously for 3 days, 2 cycles CHOP
(cyclophosphamide vincristine, doxorubicin, prednisone)
1 cycle with 2-chlorodeoxyadenosine (4 mg/mq by con-
tinuous IV infusion daily for 7 days).
On 30 August 2000 she was admitted to our hospital
with lymphocytosis, multiple lymph nodes,
hepatomegaly, splenomegaly, and cytopenia caused by
extensive bone marrow involvement. Furthermore she
had intestinal bleeding from duodenal small arterioles.
Blood tests on admission were: hemoglobin 4.7 gr/dl,
white blood cell count 20.9 x 10 9/L (neutrophyls 1%,
lymphocytes 99%), platelet count 3 x 10 9/L, lactate
dehydrogenase 266 IU/l, beta-2-microglobulin 7.1
ug/ml, total serum protein 4.6 gr/L, gamma-globulin 0.35
gr/L, renal and hepatic function blood tests normal. After
intestinal bleeding resolution she underwent salvage
treatment with alemtuzumab, a humanized monoclonal
antibody anti CD 52. The drug was given as intravenous
infusion at a dose increasing from 3 mg to 30 mg three
times every week. She had prophylactic oral treatment
with itraconazole (400 mg daily), trimethoprim-sul-
famethoxazole, acyclovir. The monoclonal antibody was
discontinued after a total dose of 163 mg because of the
onset of fever and profound granulocytopenia (neutro-
phyls <0.1x109/L). Blood cultures yielded
Corynebacterium propinquum and Staphylococcus coag-
ulase negative. She was treated with amikacin, cef-
tazidime and vancomycin without remission of fever
although blood cultures became negative.
A computerised tomographic (CT) chest scan revealed
a pulmonary infiltrate in the median field, 3 x 4 cm in
diameter with halo sign. Bronchial washing culture
yielded Aspergillus Flavus. At the same time the patient
developed left hemiparesis. A cranial CT scan without
contrast in the first 24 hours was negative, but the mag-
netic resonance imaging (MRI) of the brain after 1 month
of treatment revealed a right frontal-parietal lesion, 2 x
1,5 cm in diameter, with ring enhancement and perile-
sional oedema. Aspergillus antigen and antibodies were
repeatedly negative. Severe thrombocytopenia (5 x 109/l)
prevented invasive procedures. On October 25th 2000,
treatment with amphotericin B deoxycolate was begun
(1 mg/kg/day). There was remission of fever and
improvement of neurological symptoms after a few
days, but neutropenia persisted for the whole duration of
hospitalisation (60 days). After 20 days of amphotericin
B therapy (total dose 775 mg) a CT scan of the chest
showed increased size of the pulmonary lesion. The
magnetic resonance imaging (MRI) of the brain, after 1
month of treatment, revealed a right frontal-parietal
lesion, 2 x 1,5 cm in diameter, with ring enhancement
and perilesional oedema. As the patient requested dis-
charge from hospital, amphotericin B (total dose 1255
mg) was stopped and treatment with voriconazole was
started at the dosage of 200 mg twice a day.
Voriconazole was well tolerated, the only collateral
effects were mild and transient visual disturbances and
increase of serum aminotransferase concentrations
below five-fold increase of baseline values.
After 50 days of treatment with voriconazole a lung
CT scan showed a significant reduction of the lesion. A
brain MRI revealed resolution of the right frontal-parietal
lesion (figure 1) and appearance of a left frontal abscess,
1 cm in diameter. The patient was asymptomatic and
continued with voriconazole. As an outpatient she
underwent palliation chemotherapy with intermittent
daunorubicin, methotrexate, vinblastine and etoposide
alone or in combination. During these therapies the
patient developed repeated neutropenia . However after
4 months of treatment a brain MRI showed only resid-
ual lesions (figure 2). Chest TC scans in April and June
2001 revealed significant improvement of pulmonary
lesion. 
In July 2001 the patient was admitted to our depart-
ment and died because of progression of hematologic
disease. During this hospitalisation, chest X-ray was neg-
ative. She continued voriconazole until the death.
Invasive aspergillosis is one of the more lethal oppor-
tunistic infections in immunocompromised patients and
underlying hematological malignancies are one of the
major risk factors for its onset.
The infection localises above all in lung, sinus, brain
and mastoid process, but can spread to every organ.
Usually cerebral aspergillosis is secondary to lung locali-
sation due to embolic dissemination of fungus 2,3,7-9.
Aspergillus species typically involves blood vessels pro-
ducing thrombotic infarction. In the brain the more com-
mon histopathological features are areas of hemorrhagic
or ischemic encephalomalacia and single or multiple
abscesses; leptomeningeal localisation is rare 7.
Symptoms of cerebral aspergillosis are focal neurological
defects, alteration of mental status, seizures 1.
Standard therapy of aspergillosis is amphotericin B
deoxycholate; other effective drugs against Aspergillus
species are lipid formulations of amphotericin B and itra-
conazole 9,10.The most recent reviews about outcome and
therapeutic response in invasive aspergillosis show limit-
ed effectiveness of available drugs.
Denning et al reviewed 1223 cases of invasive
aspergillosis treated with amphotericin B deoxycholate or
itraconazole from 1972 to 1995. The outcome was influ-
enced by the underlying disease: patients with liver trans-
plantation, bone marrow transplantation and AIDS had
the worst prognosis with mortality range from 93% to
81%;in the contest of leukemia and neutropenia mortali-
ty was 77%. The mortality was also influenced by the
site of infection: cerebral localization had a mortality of
99% 4.
Lin et al reported a systematic review of 1941 patients
with invasive aspergillosis treated from 1995 with princi-
pally amphotericin B or its lipid formulations and itra-
conazole. Also in their report the outcome was worst in
patients with AIDS, bone marrow and some solid organ
transplantations; the mortality in patients with leucemia
and lymphoma was 50%. Prognosis was negatively influ-
enced by neutropenia. In the patients with disseminated
or cerebral aspergillosis the mortality was 88% 6.
Patterson et al reported a retrospective survey of 595
cases of invasive aspergillosis treated between 1994 and
1995 with amphotericin B, amphotericin B lipid formula-
tions or itraconazole. In this report the mean of therapeu-
tic failures was 36%; the outcome was worse in patients
with bone marrow transplantation and other hematolog-
ical diseases, it was related to the severity of immunode-
pression and to the site of infection with the lowest ther-
apeutic response in cerebral aspergillosis ( 9% )5.
The outcome of invasive aspergillosis is also influ-
enced by a high index of clinical suspicion and early
appropriate treatment 11-13.
The high rate of mortality in cerebral aspergillosis is
outlined by other authors who reported more limited
series of patients.
In the series of 118 patients affected by acute
leukaemia reported by Sparano et al 6% developed
proven or probable cerebral aspergillosis and all died
within 32 days from the onset of symptoms (the median
was 7 days); no data were available on antifungal treat-
ment 1.
Pagano et al reported 14 patients affected by acute
leukaemia who developed cerebral aspergillosis; all the
patients died within a median time of 5 days from the
onset of neurological symptoms in spite of early treat-
ment with amphotericin B deoxycholate 3.
In cerebral aspergillosis amphotericin B has been vari-
ably associated with local installation of the same drug,
flucytosine, itraconazole and surgical treatment. Some
cases responded well to liposomal amphotericin at high
dosage 8,14.
High mortality of cerebral aspergillosis could be sec-
ondary to poor penetration across the brain-blood barri-
er, variable bio-availability, high toxicity and mediocre
activity of antifungal drugs at present available 10,15.
Major concentration in the brain of the lipid-associated
preparations of amphotericin B has not been correlated
to a major efficacy yet 16.
Voriconazole is a new orally active antifungal triazole
with potent activity against species of Aspergillus in
vitro and in animal models 17.
In literature some sporadic cases of cerebral
aspergillosis in hematologic patients, treated with
voriconazole because of resistance to standard therapy,
have been reported.
In a case reported by Schwart et al a patient affected
by refractory acute leukaemia with an aspergillar abscess
and meningitis obtained recovery after 5 months of
treatment with voriconazole 18.
Machetti et al reported a patient, who had undergone
aploidentic allo-transplantation for acute lymphoblastic
leukaemia, with probable cerebral aspergillosis treated
with voriconazole obtaining an initial regression of neu-
rological symptoms before patient’s death due to unre-
lated infection 19.
Recently in an immunocompromised patient popula-
tion affected by invasive aspergillosis, treated with
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Figure 1. Brain MRI scan (with injection of gadolinium-containing
contrast medium) showing a right frontal-parietal lesion with ring
enhancement and perilesional oedema before treatment with
voriconazole (left panel) and its evolution in residual lesion after
50 days of therapy (right panel). Figure 2. Brain MRI scan with intravenous contrast showing thenew left frontal abscess after 50 days of treatment with voricona-
zole and its evolution in residual lesion after 4 months of therapy.
voriconazole as salvage or primary treatment, there was
16% of good response in patients with cerebral
aspergillosis 20.
Recently in a multicenter randomized trial voricona-
zole was proven more effective than amphotericin B as
primary therapy in invasive aspergillosis (successful out-
comes in 52.8% in the voriconazole group and 31.6% in
the amphotericin B group) and retrospective stratifica-
tion according to the site of infection did not change the
results 21.
In our patient there were immunodepression with
hypogammaglobulinemia inherent to the primary dis-
ease, several previous chemotherapy regimens, neutrope-
nia caused by infiltration of bone marrow. The patient
was treated with alemtuzumab, a humanized monoclon-
al antibody directed against CD52, an antigen expressed
on T and B lymphocytes; this drug was responsible for a
more severe neutropenia (neutrophils < 0.1 x 109/L ) and
responsible not only for further antibody reduction in a
patient who had severe basal hypogammaglobulinemia,
but also for further immunodepression also T-related.
The use of this novel and effective therapy in LLC has
been related to a high incidence of opportunistic infec-
tions, including cases of aspergillosis, likely to be related
to the profound lymphopenia; opportunistic infections
were reduced after introduction of mandatory prophylac-
tic antimicrobial therapy 22-26. Our patient underwent
treatment with itraconazole as antifungal prophylaxis
without success. In our patient a moderate response of
systemic symptoms to amphotericin B was obtained;
however after a month of therapy a large brain localisa-
tion was visible and lung infiltrates were increased. The
utilisation of voriconazole as oral administration was the
patient’s choice, which permitted her to be discharged.
Oral voriconazole was also just as effective in a patient
with a prolonged period of neutropenia and also lym-
phopenia secondary to administration of humanised
monoclonal anti CD52. Despite this, the patient was able
to periodically undergo palliative chemotherapy for her
progressive hematologic disease, with constant improve-
ment of radiologic picture and without any clinical symp-
toms of fungal infection. Voriconazole is usually given by
intravenous infusion and then orally if possible.
Voriconazole was given orally to our patient from the
beginning, because of her wish to be discharged as soon
as possible. As in the cases treated with intravenous
voriconazole reported in the literature 18-21, the oral
administration was quite rapidly effective also in brain
localisation without important side-effects.  This case
shows that voriconazole is active in invasive aspergillosis
with cerebral localisation refractory to standard therapy. 
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